 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1993 | Volume 119 Issue 12 | Pages 1198-1208
Glucocorticoids are pleiotropic hormones that at pharmacologic doses prevent or suppress inflammation and other immunologically mediated processes. At the molecular level, glucocorticoids form complexes with specific receptors that migrate to the nucleus where they interact with selective regulatory sites within DNA; this results in positive and negative modulation of several genes involved in inflammatory and immune responses. At the cellular level, glucocorticoids inhibit the access of leukocytes to inflammatory sites; interfere with the functions of leukocytes, endothelial cells, and fibroblasts; and suppress the production and the effects of humoral factors involved in the inflammatory response. Clinically, several modes of glucocorticoid administration are used, depending on the disease process, the organ involved, and the extent of involvement. High doses of daily glucocorticoids are usually required in patients with severe diseases involving major organs, whereas alternate-day regimens may be used in patients with less aggressive diseases. Intravenous glucocorticoids (pulse therapy) are frequently used to initiate therapy in patients with rapidly progressive, immunologically mediated diseases. The benefits of glucocorticoid therapy can easily be offset by severe side effects; even with the greatest care, side effects may occur. Moreover, for certain complications (for example, infection diathesis, peptic ulcer, osteoporosis, avascular necrosis, and atherosclerosis), other drug toxicities and pathogenic factors overlap with glucocorticoid effects. Minimizing the incidence and severity of glucocorticoid-related side effects requires carefully decreasing the dose; using adjunctive disease-modifying immunosuppressive and anti-inflammatory agents; and taking general preventive measures.
Author and Article Information
An edited summary of a Clinical Staff Conference held 30 December 1992 at the Amphitheater, Building 10, Bethesda, Maryland. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services.
NIH CONFERENCE
Glucocorticoid Therapy for Immune-mediated Diseases: Basic and Clinical Correlates
Authors who wish to cite a section on the conference and specifically indicate its author may use this example for the form of reference:
Chrousos GP. Mechanisms of action, pp 1198-1200. In: Boumpas DT, moderator. Glucocorticoid therapy for immune mediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119:1198-1208.
Requests for Reprints: Dimitrios T. Boumpas, MD, National Institutes of Health, Building 10, Room 3N-112, Bethesda, MD 20892.
This article has been cited by other articles:
|
|
 |
|
  Y. Takizawa, S. Inokuma, Y. Tanaka, K. Saito, T. Atsumi, M. Hirakata, H. Kameda, S. Hirohata, H. Kondo, S. Kumagai, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population Rheumatology, June 24, 2008; (2008) ken231v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. ROWIN Etanercept Treatment in Myasthenia Gravis Ann. N.Y. Acad. Sci., June 1, 2008; 1132(1): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J N Hoes, J W G Jacobs, M Boers, D Boumpas, F Buttgereit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, G Esselens, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases Ann Rheum Dis, December 1, 2007; 66(12): 1560 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Al-Rayes, R. Al-Swailem, M. Arfin, S. Sobki, S. Rizvi, and M. Tariq Lupus Around the World: Systemic lupus erythematosus and infections: a retrospective study in Saudis Lupus, September 1, 2007; 16(9): 755 - 763. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani Role of Chemokines in Endocrine Autoimmune Diseases Endocr. Rev., August 1, 2007; 28(5): 492 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Miller, D. Branstetter, A. Armstrong, B. Kennedy, J. Jones, L. Cowan, J. Bussiere, and W. C. Dougall Receptor Activator of NF-{kappa}B Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection J. Immunol., July 1, 2007; 179(1): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. KLETSAS, H. PRATSINIS, V. GIONI, K. PILICHOS, A. M. YIACOUMETTIS, and S. TSAGARAKIS Prior Chronic in Vivo Glucocorticoid Excess Leads to an Anabolic Phenotype and an Extension of Cellular Life Span of Skin Fibroblasts in Vitro Ann. N.Y. Acad. Sci., April 1, 2007; 1100(1): 449 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Liberman, D. Refojo, J. Druker, M. Toscano, T. Rein, F. Holsboer, and E. Arzt The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction FASEB J, April 1, 2007; 21(4): 1177 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Arafah Hypothalamic Pituitary Adrenal Function during Critical Illness: Limitations of Current Assessment Methods J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3725 - 3745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doan and E. Massarotti Rheumatoid Arthritis: An Overview of New and Emerging Therapies J. Clin. Pharmacol., July 1, 2005; 45(7): 751 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Zervolea, H. Pratsinis, S. Tsagarakis, N. Karavitaki, D. Stathakos, N. Thalassinos, and D. Kletsas The impact of chronic in vivo glucocorticoid excess on the functional characteristics of human skin fibroblasts obtained from patients with endogenous Cushing's syndrome Eur. J. Endocrinol., June 1, 2005; 152(6): 895 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rotondi, A. Falorni, A. De Bellis, S. Laureti, P. Ferruzzi, P. Romagnani, A. Buonamano, E. Lazzeri, C. Crescioli, M. Mannelli, et al. Elevated Serum Interferon-{gamma}-Inducible Chemokine-10/CXC Chemokine Ligand-10 in Autoimmune Primary Adrenal Insufficiency and in Vitro Expression in Human Adrenal Cells Primary Cultures after Stimulation with Proinflammatory Cytokines J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2357 - 2363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Narain, H. B. Richards, M. Satoh, M. Sarmiento, R. Davidson, J. Shuster, E. Sobel, P. Hahn, and W. H. Reeves Diagnostic Accuracy for Lupus and Other Systemic Autoimmune Diseases in the Community Setting Arch Intern Med, December 13, 2004; 164(22): 2435 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gedalia and A. K. Shetty Chronic Steroid and Immunosuppressant Therapy in Children Pediatr. Rev., December 1, 2004; 25(12): 425 - 434. [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. B. P. Costa Rosa Exercise as a Time-conditioning Effector in Chronic Disease: a Complementary Treatment Strategy Evid. Based Complement. Altern. Med., June 1, 2004; 1(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. U. DE MARTINO, S. ALESCI, G. P. CHROUSOS, and T. KINO Interaction of the Glucocorticoid Receptor and the Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII): Implications for the Actions of Glucocorticoids on Glucose, Lipoprotein, and Xenobiotic Metabolism Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 72 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. ELENKOV Glucocorticoids and the Th1/Th2 Balance Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 138 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tommasini and O. Cantoni Dexamethasone Promotes Toxicity in U937 Cells Exposed to Otherwise Nontoxic Concentrations of Peroxynitrite: Pivotal Role for Lipocortin 1-Mediated Inhibition of Cytosolic Phospholipase A2 Mol. Pharmacol., April 1, 2004; 65(4): 964 - 972. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]
|
|
|
|
|
|
K. De Bosscher, W. Vanden Berghe, and G. Haegeman The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression Endocr. Rev., August 1, 2003; 24(4): 488 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Castro-Lizano, C. Calleja, G. Galindo-Rodriguez, and J. A. Avina-Zubieta Letter to the Editor Lupus, August 1, 2003; 12(8): 648 - 650. [PDF]
|
|
|
|
 |
|
 E. S. Van Amersfoort, T. J. C. Van Berkel, and J. Kuiper Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock Clin. Microbiol. Rev., July 1, 2003; 16(3): 379 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dayyani, K.-U. Belge, M. Frankenberger, M. Mack, T. Berki, and L. Ziegler-Heitbrock Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes J. Leukoc. Biol., July 1, 2003; 74(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Reading, J. B. Moore, and G. L. Smith Steroid Hormone Synthesis by Vaccinia Virus Suppresses the Inflammatory Response to Infection J. Exp. Med., May 19, 2003; 197(10): 1269 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Hu, W.-P. Li, C. Meng, and L. B. Ivashkiv Inhibition of IFN-{gamma} Signaling by Glucocorticoids J. Immunol., May 1, 2003; 170(9): 4833 - 4839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Friedman, C. Newton, and T. W. Klein Microbial Infections, Immunomodulation, and Drugs of Abuse Clin. Microbiol. Rev., April 1, 2003; 16(2): 209 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Cavagnaro, S Berezin, and M S Medow Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis Arch. Dis. Child., April 1, 2003; 88(4): 342 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Beishuizen and L. G. Thijs Review: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis Innate Immunity, February 1, 2003; 9(1): 3 - 24. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Lill-Elghanian, K. Schwartz, L. King, and P. Fraker Glucocorticoid-Induced Apoptosis in Early B Cells from Human Bone Marrow Experimental Biology and Medicine, October 1, 2002; 227(9): 763 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Beglinger and L Degen Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function Gut, July 1, 2002; 51(90001): i45 - 49. [Abstract] [Full Text]
|
|
|
|
|
|
J. W.J. BIJLSMA, A. A. VAN EVERDINGEN, M. HUISMAN, R. N.J.T.L. DE NIJS, and J. W.G. JACOBS Glucocorticoids in Rheumatoid Arthritis: Effects on Erosions and Bone Ann. N.Y. Acad. Sci., June 1, 2002; 966(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. ELENKOV and G. P. CHROUSOS Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity Ann. N.Y. Acad. Sci., June 1, 2002; 966(1): 290 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. TANAKA, T. KOBAYASHI, K. NAKANISHI, M. OKUBO, M. ODAWARA, T. MURASE, M. HASHIMOTO, G. WATANABE, H. MATSUSHITA, H. INOKO, et al. Corticosteroid-Responsive Diabetes Mellitus Associated with Autoimmune Pancreatitis: Pathological Examinations of the Endocrine and Exocrine Pancreas Ann. N.Y. Acad. Sci., April 1, 2002; 958(1): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Franchimont, J. Galon, M. S. Vacchio, S. Fan, R. Visconti, D. M. Frucht, V. Geenen, G. P. Chrousos, J. D. Ashwell, and J. J. O'Shea Positive Effects of Glucocorticoids on T Cell Function by Up-Regulation of IL-7 Receptor {alpha} J. Immunol., March 1, 2002; 168(5): 2212 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Almawi and O. K. Melemedjian Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor J. Leukoc. Biol., January 1, 2002; 71(1): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. GALON, D. FRANCHIMONT, N. HIROI, G. FREY, A. BOETTNER, M. EHRHART-BORNSTEIN, J. J. O'SHEA, G. P. CHROUSOS, and S. R. BORNSTEIN Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells FASEB J, January 1, 2002; 16(1): 61 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Gudbjornsson, U I Juliusson, and F V Gudjonsson Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice Ann Rheum Dis, January 1, 2002; 61(1): 32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miura, R. Ouchida, N. Yoshikawa, K. Okamoto, Y. Makino, T. Nakamura, C. Morimoto, I. Makino, and H. Tanaka Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-kappa B-dependent Transcription by Ursodeoxycholic Acid J. Biol. Chem., December 7, 2001; 276(50): 47371 - 47378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kino, R. H. Stauber, J. H. Resau, G. N. Pavlakis, and G. P. Chrousos Pathologic Human GR Mutant Has a Transdominant Negative Effect on the Wild-Type GR by Inhibiting Its Translocation into the Nucleus: Importance of the Ligand-Binding Domain for Intracellular GR Trafficking J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5600 - 5608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tanaka, T. Kobayashi, K. Nakanishi, M. Okubo, T. Murase, M. Hashimoto, G. Watanabe, H. Matsushita, Y. Endo, H. Yoshizaki, et al. Evidence of Primary {beta}-Cell Destruction by T-Cells and {beta}-Cell Differentiation From Pancreatic Ductal Cells in Diabetes Associated With Active Autoimmune Chronic Pancreatitis Diabetes Care, September 1, 2001; 24(9): 1661 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sultan, D. Evoy, A. S. Eldin, M. Eldeeb, and N. Elmehairy Atraumatic Acute Upper Limb Ischemia: A Series of 64 Patients in a Middle East Tertiary Vascular Center and Literature Review Vascular and Endovascular Surgery, May 1, 2001; 35(3): 181 - 197. [Abstract] [PDF]
|
|
|
|
|
|
F. T. Bergh, T. Kümpfel, A. Grasser, R. Rupprecht, F. Holsboer, and C. Trenkwalder Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1610 - 1615. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Castagliuolo, K. Karalis, L. Valenick, A. Pasha, S. Nikulasson, M. Wlk, and C. Pothoulakis Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats Am J Physiol Gastrointest Liver Physiol, April 1, 2001; 280(4): G539 - G545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Eberhardt, A. Yeager-Jones, and H. C. Blair Regional Trabecular Bone Matrix Degeneration and Osteocyte Death in Femora of Glucocorticoid- Treated Rabbits Endocrinology, March 1, 2001; 142(3): 1333 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ara, E. Mirapeix, P. Arrizabalaga, R. Rodriguez, C. Ascaso, R. Abellana, J. Font, and A. Darnell Circulating soluble adhesion molecules in ANCA-associated vasculitis Nephrol. Dial. Transplant., February 1, 2001; 16(2): 276 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.M. O'CONNOR, D.J. O'HALLORAN, and F. SHANAHAN The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia QJM, June 1, 2000; 93(6): 323 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Giltay, J. C. M. Fonk, B. M. E. von Blomberg, H. A. Drexhage, C. Schalkwijk, and L. J. G. Gooren In Vivo Effects of Sex Steroids on Lymphocyte Responsiveness and Immunoglobulin Levels in Humans J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1648 - 1657. [Abstract] [Full Text]
|
|
|
|
|
|
D. Franchimont, J. Galon, M. Gadina, R. Visconti, Y.-J. Zhou, M. Aringer, D. M. Frucht, G. P. Chrousos, and J. J. O'Shea Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes J. Immunol., February 15, 2000; 164(4): 1768 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Sarlis, S. J. Chanock, and L. K. Nieman Cortisolemic Indices Predict Severe Infections in Cushing Syndrome Due to Ectopic Production of Adrenocorticotropin J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 42 - 47. [Abstract] [Full Text]
|
|
|
|
|
|
I. Torsteinsdottir, L. Hakansson, R. Hallgren, B. Gudbjornsson, N.-G. Arvidson, and P. Venge Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis Rheumatology, December 1, 1999; 38(12): 1249 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Brink, B Thiele, G-R Burmester, G Trebeljahr, F Emmrich, and F Hiepe Effects of anti-CD4 antibodies on the release of IL-6 and TNF-{alpha} in whole blood samples from patients with systemic lupus erythematosus Lupus, November 1, 1999; 8(9): 723 - 730. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Poon, B. Liu, and M. B. Taubman Identification of a Novel Dexamethasone-Sensitive RNA-Destabilizing Region on Rat Monocyte Chemoattractant Protein 1 mRNA Mol. Cell. Biol., October 1, 1999; 19(10): 6471 - 6478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Vanden Berghe, E. Francesconi, K. De Bosscher, M. Resche-Rigon, and G. Haegeman Dissociated Glucocorticoids with Anti-Inflammatory Potential Repress Interleukin-6 Gene Expression by a Nuclear Factor-kappa B-Dependent Mechanism Mol. Pharmacol., October 1, 1999; 56(4): 797 - 806. [Abstract] [Full Text]
|
|
|
|
|
|
D. Franchimont, H. Martens, M.-T. Hagelstein, E. Louis, W. Dewe, G. P. Chrousos, J. Belaiche, and V. Geenen Tumor Necrosis Factor {alpha} Decreases, and Interleukin-10 Increases, the Sensitivity of Human Monocytes to Dexamethasone: Potential Regulation of the Glucocorticoid Receptor J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2834 - 2839. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. P. Karalis, E. Kontopoulos, L. J. Muglia, and J. A. Majzoub Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine PNAS, June 8, 1999; 96(12): 7093 - 7097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okamoto, H. Tanaka, H. Ogawa, Y. Makino, H. Eguchi, S.-i. Hayashi, N. Yoshikawa, L. Poellinger, K. Umesono, and I. Makino Redox-dependent Regulation of Nuclear Import of the Glucocorticoid Receptor J. Biol. Chem., April 9, 1999; 274(15): 10363 - 10371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Casadevall, E. Saperas, J. Panes, A. Salas, D. C. Anderson, J. R. Malagelada, and J. M. Pique Mechanisms underlying the anti-inflammatory actions of central corticotropin-releasing factor Am J Physiol Gastrointest Liver Physiol, April 1, 1999; 276(4): G1016 - G1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kino, A. Gragerov, J. B. Kopp, R. H. Stauber, G. N. Pavlakis, and G. P. Chrousos The HIV-1 Virion-associated Protein Vpr Is a Coactivator of the Human Glucocorticoid Receptor J. Exp. Med., January 4, 1999; 189(1): 51 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H Steer, D. T S Ma, L. Dusci, G. Garas, K. E Pedersen, and D. A Joyce Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment Ann Rheum Dis, December 1, 1998; 57(12): 732 - 737. [Abstract] [Full Text]
|
|
Article
